-
Mashup Score: 0
New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in pancreatic cancer patients.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Atebimetinib plus SOC chemo led to 6-month OS and PFS rates of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC. #pancsm https://t.co/trJWvN0zbp
-
-
Mashup Score: 9
The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The FDA granted FTD to anti-IL1RAP antibody nadunolimab as a frontline treatment in combination with gemcitabine and nab-paclitaxel for patients with metastatic PDAC with high levels of IL1RAP. #pancsm https://t.co/wli9GVJ4BA
-
-
Mashup Score: 48
PURPOSE Despite limited RCTs, neoadjuvant chemotherapy (NAC) shows promise for resectable pancreatic adenocarcinoma (rPAC). Few prospective results are available on completing the full therapeutic sequence and oncologic outcomes with NAC. METHODS The …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 Study). #PancSM Read full article. https://t.co/CXCYK9vrYC
-
-
Mashup Score: 3
A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Pancreatic Cancer Spreads to Liver or Lung Thanks to This Protein @UCSFHospitals #pancsm https://t.co/UdCTGB6Ydk
-
-
Mashup Score: 1
Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel elicited an overall response rate of 83% in a small cohort of patients with metastatic pancreatic ductal adenocarcinoma. #pancsm https://t.co/fA3whM9pfQ
-
-
Mashup Score: 51PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma - 1 month(s) ago
PURPOSEMore than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. #PancSM Read full article. https://t.co/TM9dMp53Sw
-
-
Mashup Score: 2
Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
JNJ-1900 demonstrated favorable safety, feasibility, and early efficacy outcomes in a small cohort of patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma. #pancsm https://t.co/dY9SC9dVsH
-
-
Mashup Score: 44
PURPOSE Despite limited RCTs, neoadjuvant chemotherapy (NAC) shows promise for resectable pancreatic adenocarcinoma (rPAC). Few prospective results are available on completing the full therapeutic sequence and oncologic outcomes with NAC. METHODS The …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 Study). #PancSM Read full article. https://t.co/CXCYK9vrYC
-
-
Mashup Score: 2
Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Patients with metastatic PDAC classified as racial or ethnic minority populations or as socially vulnerable had lower quality of care, which resulted in suboptimal treatment and survival outcomes. #pancsm | @DTsilimigras https://t.co/S8WJ4W9ena
-
New data from an ongoing phase 2a trial suggest that atebimetinibZA in combination with modified gemcitabine/nab-paclitaxel, may offer significant survival benefits in the first line for patients with pancreatic cancer. #pancsm https://t.co/f3OqHkbdBd